PLoS ONE (Jan 2013)

Neonatal gram negative and Candida sepsis survival and neurodevelopmental outcome at the corrected age of 24 months.

  • Timo R de Haan,
  • Loes Beckers,
  • Rogier C J de Jonge,
  • Lodewijk Spanjaard,
  • Letty van Toledo,
  • Dasja Pajkrt,
  • Aleid G van Wassenaer-Leemhuis,
  • Johanna H van der Lee

DOI
https://doi.org/10.1371/journal.pone.0059214
Journal volume & issue
Vol. 8, no. 3
p. e59214

Abstract

Read online

ObjectivesTo evaluate the long term neurodevelopmental outcome of premature infants exposed to either gram- negative sepsis (GNS) or neonatal Candida sepsis (NCS), and to compare their outcome with premature infants without sepsis.MethodsHistorical cohort study in a population of infants born at ResultsOf 1362 patients, 55 suffered from GNS and 29 suffered from NCS; cumulative incidence 4.2% and 2.2%, respectively. During the follow-up period the mortality rate was 34% for both GNS and NCS and 5% for UC. The adjusted Odds Ratio (OR) [95% CI] for adverse outcome in the GNS group compared to the NCS group was 1.4 [0.4-4.9]. The adjusted ORs [95% CI] for adverse outcome in the GNS and NCS groups compared to the UC group were 4.8 [1.5-15.9] and 3.2 [0.7-14.7], respectively.ConclusionsWe found no statistically significant difference in outcome at the corrected age of 24 months between neonatal GNS and NCS cases. Suffering from either gram-negative or Candida sepsis increased the odds for adverse outcome compared with an uncomplicated neonatal period.